US President Trump announced a phased tariff of up to 200% on generic drug imports to boost domestic manufacturing. India, the 'pharmacy of the world' with $9.7B in pharma exports to the US (38% of total), faces significant export disruption. However, US-based subsidiaries of Indian firms may reduce the direct impact.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Tariff Plan Start Date: August 1, 2026
- ›Final Tariff Rate: 200%
- ›Target this Data: India's pharma exports to US in 2025 = $9.7 billion (38% of total $25.8B)
- ›Target this Data: Trump tariff timeline – 0% (2 yrs), 100% (year 3), 200% (from year 4)
- ›Target this Institution/Report: Global Trade Research Initiative (GTRI) report cited for export data
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.